These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12891183)

  • 1. Does race matter in heart failure?
    Yancy CW
    Am Heart J; 2003 Aug; 146(2):203-6. PubMed ID: 12891183
    [No Abstract]   [Full Text] [Related]  

  • 2. Race and a heart drug.
    Peota C
    Minn Med; 2005 Mar; 88(3):11. PubMed ID: 15852585
    [No Abstract]   [Full Text] [Related]  

  • 3. Amerindian genetic ancestry is associated with higher survival rates compared to African and European ancestry in Brazilian patients with heart failure.
    Cardena MM; Ribeiro-dos-Santos A; Santos S; Mansur AJ; Pereira AC; Fridman C
    Int J Cardiol; 2014 Sep; 176(2):527-8. PubMed ID: 25088152
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymorphisms of adrenergic receptors and the risk of heart failure.
    Little J; Gwinn M; Khoury M
    N Engl J Med; 2003 Jan; 348(5):468-70; author reply 468-70. PubMed ID: 12557865
    [No Abstract]   [Full Text] [Related]  

  • 5. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P; Ziesche S; Johnson G; Cohn JN
    J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug success signals a new trend. A "race-based" medication is a step toward individualized care.
    Heart Advis; 2005 Apr; 8(4):4-5. PubMed ID: 16138392
    [No Abstract]   [Full Text] [Related]  

  • 7. Race and responsiveness to drugs for heart failure.
    Ofili E; Flack J; Gibbons G
    N Engl J Med; 2001 Sep; 345(10):767; author reply 767-8. PubMed ID: 11547752
    [No Abstract]   [Full Text] [Related]  

  • 8. The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure.
    Chen G; Zhou X; Pathak A; Dorn GW; Kranias EG
    Cardiology; 2009; 112(3):224-31. PubMed ID: 18698139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenergic-receptor polymorphisms and heart failure.
    Hajjar RJ; MacRae CA
    N Engl J Med; 2002 Oct; 347(15):1196-9. PubMed ID: 12374881
    [No Abstract]   [Full Text] [Related]  

  • 10. Race and Beta-Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self-Reported Race and Proportion of African Genetic Ancestry.
    Luzum JA; Peterson E; Li J; She R; Gui H; Liu B; Spertus JA; Pinto YM; Williams LK; Sabbah HN; Lanfear DE
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29739794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race-related differences in heart failure therapies: simply black and white or shades of grey?
    Shroff GR; Taylor AL; Colvin-Adams M
    Curr Cardiol Rep; 2007 May; 9(3):178-81. PubMed ID: 17470329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Have we witnessed the rise and fall of race-specific drugs?
    Coons SJ
    Clin Ther; 2009 Mar; 31(3):620-2. PubMed ID: 19393852
    [No Abstract]   [Full Text] [Related]  

  • 13. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner DV; Dries DL; Domanski MJ; Cohn JN
    N Engl J Med; 2001 May; 344(18):1351-7. PubMed ID: 11333991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
    Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and responsiveness to drugs for heart failure.
    Masoudi FA; Havranek EP
    N Engl J Med; 2001 Sep; 345(10):767; author reply 767-8. PubMed ID: 11547751
    [No Abstract]   [Full Text] [Related]  

  • 16. Racial differences in the outcome of left ventricular dysfunction.
    Dries DL; Exner DV; Gersh BJ; Cooper HA; Carson PE; Domanski MJ
    N Engl J Med; 1999 Feb; 340(8):609-16. PubMed ID: 10029645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial differences in outcome and treatment effect in congestive heart failure.
    Mathew J; Wittes J; McSherry F; Williford W; Garg R; Probstfield J; Yusuf S;
    Am Heart J; 2005 Nov; 150(5):968-76. PubMed ID: 16290973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
    Yancy CW; Fowler MB; Colucci WS; Gilbert EM; Bristow MR; Cohn JN; Lukas MA; Young ST; Packer M;
    N Engl J Med; 2001 May; 344(18):1358-65. PubMed ID: 11333992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.
    Small KM; Wagoner LE; Levin AM; Kardia SL; Liggett SB
    N Engl J Med; 2002 Oct; 347(15):1135-42. PubMed ID: 12374873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function.
    McNamara DM
    Congest Heart Fail; 2004; 10(6):302-8. PubMed ID: 15591845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.